<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Huang M</submitter><funding>Basic Scientific Research Funds of Department of Education of Zhejiang Province</funding><funding>Zhejiang Medical and Health Science and Technology Plan Project</funding><funding>the administration of traditional Chinese Medicine of Zhejiang province</funding><funding>the Natural Science Foundation of Zhejiang Province</funding><funding>the National Natural Science Foundation of China</funding><pagination>152</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12487359</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Ulcerative colitis (UC), a chronic inflammatory bowel disease, remains an unmet medical need. Lindera aggregata, a traditional Chinese medicine used in treating gastrointestinal disorders, has demonstrated anti-UC efficacy, though its bioactive components are poorly characterized. Isolinderalactone (ILDL), a characteristic sesquiterpene lactone isolated from Lindera aggregata, has been demonstrated anti-cancer properties. However, its therapeutic potential in UC remains unexplored.&lt;h4>Methods&lt;/h4>Lipopolysaccharide (LPS)-induced RAW264.7 inflammatory cell model was used to screen the anti-inflammatory properties of Lindera aggregata's characteristic compounds in vitro. DSS induced UC mouse model was used to study the anti-UC efficacy of ILDL in vivo. Transcriptomic was u</pubmed_abstract><journal>Chinese medicine</journal><pubmed_title>Isolinderalactone regulates macrophage polarization and efferocytosis by activating the LXRα pathway against ulcerative colitis.</pubmed_title><pmcid>PMC12487359</pmcid><funding_grant_id>2024KY917</funding_grant_id><funding_grant_id>GZY-KJS-ZJ-2025-080, 2024ZF056</funding_grant_id><funding_grant_id>KYYB2023002, KYYB2023017</funding_grant_id><funding_grant_id>LMS25H280001, LMS25H030001, Q24H280064</funding_grant_id><funding_grant_id>82300589, 82360805</funding_grant_id><pubmed_authors>Zeng L</pubmed_authors><pubmed_authors>Li F</pubmed_authors><pubmed_authors>Huang M</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Shi Y</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Dou X</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Lin C</pubmed_authors><pubmed_authors>Liang G</pubmed_authors><pubmed_authors>Lan M</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Sun J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Isolinderalactone regulates macrophage polarization and efferocytosis by activating the LXRα pathway against ulcerative colitis.</name><description>&lt;h4>Background&lt;/h4>Ulcerative colitis (UC), a chronic inflammatory bowel disease, remains an unmet medical need. Lindera aggregata, a traditional Chinese medicine used in treating gastrointestinal disorders, has demonstrated anti-UC efficacy, though its bioactive components are poorly characterized. Isolinderalactone (ILDL), a characteristic sesquiterpene lactone isolated from Lindera aggregata, has been demonstrated anti-cancer properties. However, its therapeutic potential in UC remains unexplored.&lt;h4>Methods&lt;/h4>Lipopolysaccharide (LPS)-induced RAW264.7 inflammatory cell model was used to screen the anti-inflammatory properties of Lindera aggregata's characteristic compounds in vitro. DSS induced UC mouse model was used to study the anti-UC efficacy of ILDL in vivo. Transcriptomic was u</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-04T01:51:47.559Z</modification><creation>2026-05-04T03:14:13.741Z</creation></dates><accession>S-EPMC12487359</accession><cross_references><pubmed>41029870</pubmed><doi>10.1186/s13020-025-01216-9</doi></cross_references></HashMap>